Show simple item record

dc.contributor.authorVadhan-Raj, S
dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorVenerito, M
dc.contributor.authorRiess, H
dc.contributor.authorO'Reilly, EM
dc.contributor.authorOverman, MJ
dc.contributor.authorZhou, X
dc.contributor.authorVijapurkar, U
dc.contributor.authorKaul, S
dc.contributor.authorWildgoose, P
dc.contributor.authorKhorana, AA
dc.date.accessioned2019-11-19T16:01:08Z
dc.date.available2019-11-19T16:01:08Z
dc.date.issued2019en
dc.identifier.citationVadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, et al. Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: results from a prespecified subgroup analysis of the CASSINI study. J Clin Oncol. 2019;37(15_suppl):4016-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.4016en
dc.identifier.urihttp://hdl.handle.net/10541/622471
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4016en
dc.titleRivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: results from a prespecified subgroup analysis of the CASSINI studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Houston, TXen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record